Omega-3 (EPA/DHA) vs Vesugen
A side-by-side research comparison of Omega-3 (EPA/DHA) and Vesugen across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Omega-3 (EPA/DHA) | Vesugen |
|---|---|---|
| Full name | Omega-3 Fatty Acids (EPA + DHA) | Vesugen (Lys-Glu-Asp Vascular Bioregulator) |
| Category | Cardiovascular | Cardiovascular |
| Status | Dietary supplement / FDA-approved (Rx fish oil) | Research compound (peptide bioregulator) |
| Mechanism | EPA/DHA incorporate into cell membranes, displacing arachidonic acid and reducing pro-inflammatory eicosanoid production. Generate resolvins and protectins for active inflammation resolution. Activate PPARγ and inhibit NF-κB. | As a signal peptide (Lys-Glu-Asp), it is proposed to enter cells and regulate gene expression in vascular tissue, supporting endothelial function, vascular tone, and normal vessel-wall maintenance. |
| Molecular weight | EPA: 302.45 Da, DHA: 328.49 Da | ~390 Da |
| Half-life | ~48-72 hours (membrane incorporation) | Short (peptide) |
| Bioavailability | Triglyceride form: ~70%; ethyl ester: ~30-40%; phospholipid (krill): ~85% | Oral (encapsulated) or subcutaneous |
| Typical dose | 2-4g combined EPA+DHA | ~1-2 capsules/day or short injectable courses |
| Frequency | Daily with meals | Once daily |
| Route | Oral (softgel, liquid) | Oral capsule or subcutaneous |
Omega-3 (EPA/DHA) reported benefits
- Triglyceride reduction (25-45%)
- Anti-inflammatory (SPM production)
- Cardiac rhythm stabilization
- Brain and cognitive support
- Joint inflammation reduction
- Membrane fluidity optimization
Vesugen reported benefits
- Vascular/endothelial support
- Proposed vascular tissue regulation
- Short course-based protocol
- Part of bioregulator longevity systems
Related comparisons
Research and educational reference only. Not medical advice.